PELTHOS THERAPEUTICS INC
PTHSNYSE AMERICANTrading Snapshot
- Day Range
- $15.68 – $16.77
- 52-Week Range
- $14.44 – $37.50
- Volume (shares)
- 4,486
- Avg Volume (shares)
- —
- Shares Outstanding
- 3.8M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $16M
- P/E Ratio
- —
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-21.82
- Dividend Yield
- —
- Dilution (1yr)
- +429.3%
PELTHOS THERAPEUTICS INC
PTHS
StockOtter · stockotter.spaceAbout PELTHOS THERAPEUTICS INC
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill,
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives Pelthos gains enhanced commercial coverage through a regional commercial health plan represent
Pelthos Therapeutics Q2 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment's July 2025 commercial launch. The company also discussed
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $5.38 per share a year ago.
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026